Low flow impact on outcomes following TAVI should be taken into account

Original title: Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Reference: Florent Le Ven, et al. J Am Coll Cardiol 62;9:792-788

A study of low flow (SVi <35ml/m2) in the context of severe aortic stenosis has shown it is a predictor of worse outcomes after surgery, even though evolution with medical treatment in these patients is even worse.  The impact of this phenomenon in TVAR is has not yet been explored.  775 procedures were analyzed retrospectively, excluding the “valve-in-valve” procedures, TAVR for other indication than severe AS, and incomplete pre-procedural sonogram studies. Finally 639 patients were included in the study.

These were divided in four groups, according to gradient and flow: normal flow with high gradient, 195 patients; normal flow with low gradient, 110 patients; low flow with high gradient, 158 patients; and low flow with low gradient, 176 patients. This last group was divided into two groups of 86 and 90 patients with >50% and <50% ejection fraction, respectively.

Mortality at 30 days resulted significantly higher in the low flow group (11% vs 6% p=0.01). Death predictors were: male sex, diabetes, glomerular filtration rate, pulmonary hypertension, and

Those with reduced flow saw a higher mortality rate than the normal flow group, both cardiac and non-cardiac. On the contrary, the normal flow/high gradient group, normal flow/low gradient and low flow/high gradient groups presented a similar evolution. Among those that combined low flow and low gradient, there were no differences in all-cause mortality or cardiac mortality associated to ejection fraction. 

Conclusion:

Low flow is an independent predictor of early and late mortality after TVAR but not ejection fraction or low gradient. SVi should be integrated in the risk stratification process of these patients.

Comment: 

This study offers another variable to be taken into account when considering TVAR. Even though ejection fraction showed no impact at follow up, many other studies did associate it with worse evolution.

Courtesy of Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation, Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...